-
1
-
-
0034596948
-
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
-
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of experimental medicine. 2000; 192:1027-1034.
-
(2000)
The Journal of experimental medicine
, vol.192
, pp. 1027-1034
-
-
Freeman, G.J.1
Long, A.J.2
Iwai, Y.3
Bourque, K.4
Chernova, T.5
Nishimura, H.6
Fitz, L.J.7
Malenkovich, N.8
Okazaki, T.9
Byrne, M.C.10
Horton, H.F.11
Fouser, L.12
Carter, L.13
-
2
-
-
84973581304
-
Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
-
abstr TPS4135
-
Charles S. Fuchs, Andrew E. Denker, Josep Tabernero, Eric Van Cutsem, Atsushi Ohtsu, Baohoang Lam, Minori Koshiji, Bang Y-J. Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2015; 33:(suppl; abstr TPS4135).
-
(2015)
J Clin Oncol
, vol.33
-
-
Fuchs, C.S.1
Denker, A.E.2
Tabernero, J.3
Van Cutsem, E.4
Ohtsu, A.5
Lam, B.6
Koshiji, M.7
Bang, Y.-J.8
-
3
-
-
84973527924
-
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study
-
abstr 6
-
Le DT, Bendell JC, Calvo E, Kim JW, Ascierto AP, Sharma P, Ott PA, Bono P, Jaeger D, Evans TRJ, De Braud FG, Chau I, Christensen O, et al. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. J Clin Oncol. 2016; 34:(suppl 4S; abstr 6).
-
(2016)
J Clin Oncol
, vol.34
-
-
Le, D.T.1
Bendell, J.C.2
Calvo, E.3
Kim, J.W.4
Ascierto, A.P.5
Sharma, P.6
Ott, P.A.7
Bono, P.8
Jaeger, D.9
Evans, T.R.J.10
De Braud, F.G.11
Chau, I.12
Christensen, O.13
-
4
-
-
84907270779
-
Comprehensive molecular characterization of gastric adenocarcinoma
-
Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513:202-209.
-
(2014)
Nature
, vol.513
, pp. 202-209
-
-
-
5
-
-
84932628341
-
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
-
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372:2509-2520.
-
(2015)
N Engl J Med
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
Bartlett, B.R.4
Kemberling, H.5
Eyring, A.D.6
Skora, A.D.7
Luber, B.S.8
Azad, N.S.9
Laheru, D.10
Biedrzycki, B.11
Donehower, R.C.12
Zaheer, A.13
-
6
-
-
84941797037
-
Classifying Cancers Based on T-cell Infiltration and PD-L1
-
Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015; 75:2139-2145.
-
(2015)
Cancer Res
, vol.75
, pp. 2139-2145
-
-
Teng, M.W.1
Ngiow, S.F.2
Ribas, A.3
Smyth, M.J.4
-
7
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515:563-567.
-
(2014)
Nature
, vol.515
, pp. 563-567
-
-
Herbst, R.S.1
Soria, J.C.2
Kowanetz, M.3
Fine, G.D.4
Hamid, O.5
Gordon, M.S.6
Sosman, J.A.7
McDermott, D.F.8
Powderly, J.D.9
Gettinger, S.N.10
Kohrt, H.E.11
Horn, L.12
Lawrence, D.P.13
-
8
-
-
84997787368
-
The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors
-
Romano E, Romero P. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. J Immunother Cancer. 2015; 3:15.
-
(2015)
J Immunother Cancer
, vol.3
, pp. 15
-
-
Romano, E.1
Romero, P.2
-
9
-
-
23244448471
-
EBV the prototypical human tumor virus-just how bad is it?
-
quiz 262.
-
Thorley-Lawson DA. EBV the prototypical human tumor virus-just how bad is it? J Allergy Clin Immunol. 2005; 116:251-261; quiz 262.
-
(2005)
J Allergy Clin Immunol
, vol.116
, pp. 251-261
-
-
Thorley-Lawson, D.A.1
-
10
-
-
84891738417
-
Improved survival of gastric cancer with tumour Epstein- Barr virus positivity: an international pooled analysis
-
Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, Kijima Y, Natsugoe S, Liao LM, et al. Improved survival of gastric cancer with tumour Epstein- Barr virus positivity: an international pooled analysis. Gut. 2014; 63:236-243.
-
(2014)
Gut
, vol.63
, pp. 236-243
-
-
Camargo, M.C.1
Kim, W.H.2
Chiaravalli, A.M.3
Kim, K.M.4
Corvalan, A.H.5
Matsuo, K.6
Yu, J.7
Sung, J.J.8
Herrera-Goepfert, R.9
Meneses-Gonzalez, F.10
Kijima, Y.11
Natsugoe, S.12
Liao, L.M.13
-
11
-
-
84922918896
-
Deregulation of immune response genes in patients with Epstein-Barr virusassociated gastric cancer and outcomes
-
e139
-
Kim SY, Park C, Kim HJ, Park J, Hwang J, Kim JI, Choi MG, Kim S, Kim KM, Kang MS. Deregulation of immune response genes in patients with Epstein-Barr virusassociated gastric cancer and outcomes. Gastroenterology. 2015; 148:137-147 e139.
-
(2015)
Gastroenterology
, vol.148
, pp. 137-147
-
-
Kim, S.Y.1
Park, C.2
Kim, H.J.3
Park, J.4
Hwang, J.5
Kim, J.I.6
Choi, M.G.7
Kim, S.8
Kim, K.M.9
Kang, M.S.10
-
12
-
-
84858206832
-
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy
-
Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18:1611-1618.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1611-1618
-
-
Green, M.R.1
Rodig, S.2
Juszczynski, P.3
Ouyang, J.4
Sinha, P.5
O'Donnell, E.6
Neuberg, D.7
Shipp, M.A.8
-
13
-
-
0842325739
-
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
-
Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004; 64:1140-1145.
-
(2004)
Cancer Res
, vol.64
, pp. 1140-1145
-
-
Blank, C.1
Brown, I.2
Peterson, A.C.3
Spiotto, M.4
Iwai, Y.5
Honjo, T.6
Gajewski, T.F.7
-
14
-
-
84879866976
-
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
-
Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013; 19:3462-3473.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 3462-3473
-
-
Chen, B.J.1
Chapuy, B.2
Ouyang, J.3
Sun, H.H.4
Roemer, M.G.5
Xu, M.L.6
Yu, H.7
Fletcher, C.D.8
Freeman, G.J.9
Shipp, M.A.10
Rodig, S.J.11
-
15
-
-
84968919518
-
Dual faces of IFN-gamma in cancer progression: a role of PD-L1 induction in the determination of pro- and anti-tumor immunity
-
Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual faces of IFN-gamma in cancer progression: a role of PD-L1 induction in the determination of pro- and anti-tumor immunity. Clin Cancer Res. 2016.
-
(2016)
Clin Cancer Res
-
-
Mandai, M.1
Hamanishi, J.2
Abiko, K.3
Matsumura, N.4
Baba, T.5
Konishi, I.6
-
16
-
-
0033178448
-
Initial and innate responses to viral infections- pattern setting in immunity or disease
-
Biron CA. Initial and innate responses to viral infections- pattern setting in immunity or disease. Curr Opin Microbiol. 1999; 2:374-381.
-
(1999)
Curr Opin Microbiol
, vol.2
, pp. 374-381
-
-
Biron, C.A.1
-
17
-
-
84936821508
-
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferoninflammatory immune gene signature
-
abstract 3001
-
Ribas A, Robert C, Hodi SF, Wolchok JD, Joshua AM, Hwu W, Weber JS, Zarour HM, Kefford R, Loboda A, Albright A, Kang SP, Ebbinghaus S, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferoninflammatory immune gene signature. J Clin Oncol. 2015; 33:(suppl; abstract 3001).
-
(2015)
J Clin Oncol
, vol.33
-
-
Ribas, A.1
Robert, C.2
Hodi, S.F.3
Wolchok, J.D.4
Joshua, A.M.5
Hwu, W.6
Weber, J.S.7
Zarour, H.M.8
Kefford, R.9
Loboda, A.10
Albright, A.11
Kang, S.P.12
Ebbinghaus, S.13
-
18
-
-
84941108977
-
Inflamed-phenotype gene expression signatures to predict benefit from the anti- PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients
-
abstr 6017
-
Seiwert TY, Burtness B, Weiss J, Eder JP, Yearley J, Murphy E, Nebozhyn M, McClanahan T, Ayers M, Lunceford JK, Mehra R, Heath K, Cheng JD, et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti- PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. J Clin Oncol. 2015; 33:(suppl; abstr 6017).
-
(2015)
J Clin Oncol
, vol.33
-
-
Seiwert, T.Y.1
Burtness, B.2
Weiss, J.3
Eder, J.P.4
Yearley, J.5
Murphy, E.6
Nebozhyn, M.7
McClanahan, T.8
Ayers, M.9
Lunceford, J.K.10
Mehra, R.11
Heath, K.12
Cheng, J.D.13
-
19
-
-
84973554030
-
Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
-
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Albright A, Cheng J, Kang P, Ebbinghaus S, Yearley J, Shankaran V, Seiwert T, Ribas A, et al. Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors. J Immunother Cancer. 2015; 3:80.
-
(2015)
J Immunother Cancer
, vol.3
, pp. 80
-
-
Ayers, M.1
Lunceford, J.2
Nebozhyn, M.3
Murphy, E.4
Loboda, A.5
Albright, A.6
Cheng, J.7
Kang, P.8
Ebbinghaus, S.9
Yearley, J.10
Shankaran, V.11
Seiwert, T.12
Ribas, A.13
-
20
-
-
85010777933
-
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
-
McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016; 2:46-54.
-
(2016)
JAMA Oncol
, vol.2
, pp. 46-54
-
-
McLaughlin, J.1
Han, G.2
Schalper, K.A.3
Carvajal-Hausdorf, D.4
Pelekanou, V.5
Rehman, J.6
Velcheti, V.7
Herbst, R.8
LoRusso, P.9
Rimm, D.L.10
-
21
-
-
33644827779
-
Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection
-
Chiaravalli AM, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R, Novario R, Capella C. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2006; 448:344-353.
-
(2006)
Virchows Arch
, vol.448
, pp. 344-353
-
-
Chiaravalli, A.M.1
Feltri, M.2
Bertolini, V.3
Bagnoli, E.4
Furlan, D.5
Cerutti, R.6
Novario, R.7
Capella, C.8
-
22
-
-
79959743018
-
Determinants of Epstein-Barr viruspositive gastric cancer: an international pooled analysis
-
Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, Corvalan AH, Carrascal E, Abdirad A, Anwar M, Hao Z, Kattoor J, Yoshiwara- Wakabayashi E, et al. Determinants of Epstein-Barr viruspositive gastric cancer: an international pooled analysis. Br J Cancer. 2011; 105:38-43.
-
(2011)
Br J Cancer
, vol.105
, pp. 38-43
-
-
Camargo, M.C.1
Murphy, G.2
Koriyama, C.3
Pfeiffer, R.M.4
Kim, W.H.5
Herrera-Goepfert, R.6
Corvalan, A.H.7
Carrascal, E.8
Abdirad, A.9
Anwar, M.10
Hao, Z.11
Kattoor, J.12
Yoshiwara-Wakabayashi, E.13
-
23
-
-
84962150072
-
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
-
Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2016.
-
(2016)
Gut
-
-
Thompson, E.D.1
Zahurak, M.2
Murphy, A.3
Cornish, T.4
Cuka, N.5
Abdelfatah, E.6
Yang, S.7
Duncan, M.8
Ahuja, N.9
Taube, J.M.10
Anders, R.A.11
Kelly, R.J.12
-
24
-
-
84928761118
-
Cancer immunology Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
-
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348:124-128.
-
(2015)
Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
Kvistborg, P.4
Makarov, V.5
Havel, J.J.6
Lee, W.7
Yuan, J.8
Wong, P.9
Ho, T.S.10
Miller, M.L.11
Rekhtman, N.12
Moreira, A.L.13
|